SAREPTA THERAPEUTICS, INC. (SRPT) Current Ratio
- Current ratio · latest quarter: Value 4.42×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.42× | Current assets / current liabilities. $2.22B ÷ $502.91M ≈ 4.42× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 2.22B USD | Assets, Current |
| Current obligations | 502.91M USD | Liabilities, Current |
| Cash and equivalents | 571.15M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 376.82M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 904.27M USD | Inventory, Net |
| Payables | 50.98M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.22B | $502.91M | $571.15M | (m) | $376.82M | $904.27M | $50.98M | (m) | 4.42× |
| 2026-03-31 | $2.31B | $499.16M | $464.45M | (m) | $394.82M | $1.00B | $70.38M | (m) | 4.63× |
| 2025-12-31 | $2.54B | $1.10B | $801.28M | (m) | $398.23M | $914.74M | $280.84M | (m) | 2.32× |
| 2025-09-30 | $2.72B | $921.42M | $613.08M | (m) | $395.74M | $1.08B | $94.02M | (m) | 2.95× |
| 2025-06-30 | $2.66B | $919.95M | $510.60M | (m) | $527.29M | $994.04M | $136.70M | (m) | 2.89× |
| 2025-03-31 | $2.43B | $605.59M | $240.87M | (m) | $659.37M | $941.43M | $156.10M | (m) | 4.02× |
| 2024-12-31 | $3.07B | $731.68M | $1.10B | (m) | $601.99M | $749.96M | $214.44M | (m) | 4.20× |
| 2024-09-30 | $2.69B | $699.49M | $197.85M | (m) | $434.52M | $565.92M | $118.77M | $91.59M | 3.84× |
| 2024-06-30 | $2.68B | $688.49M | $383.62M | $1.08B | $360.00M | $485.80M | $107.42M | $91.50M | 3.90× |
| 2024-03-31 | $2.46B | $608.71M | $427.29M | $963.45M | $378.81M | $373.53M | $91.54M | $105.59M | 4.05× |
| 2023-12-31 | $2.58B | $653.66M | $428.43M | (m) | $400.33M | $322.86M | $164.92M | $105.48M | 3.95× |
| 2023-09-30 | $2.45B | $450.74M | $541.93M | $1.19B | $318.86M | $244.01M | $87.95M | (m) | 5.44× |
| 2023-06-30 | $2.47B | $498.65M | $851.93M | $1.01B | $236.81M | $226.88M | $109.80M | (m) | 4.96× |
| 2023-03-31 | $2.49B | $536.88M | $871.67M | $1.01B | $223.84M | $202.68M | $106.71M | (m) | 4.63× |
| 2022-12-31 | $2.56B | $619.60M | $966.78M | $1.02B | $214.63M | $203.97M | $95.88M | $0.00 | 4.13× |
| 2022-09-30 | $2.63B | $602.92M | $1.04B | $1.03B | $201.51M | $221.19M | $118.46M | (m) | 4.36× |
| 2022-06-30 | $2.47B | $545.57M | $868.57M | $1.06B | $203.85M | $208.09M | $56.21M | (m) | 4.53× |
| 2022-03-31 | $2.53B | $454.96M | $1.23B | $779.55M | $178.19M | $199.00M | $54.01M | (m) | 5.56× |
| 2021-12-31 | $2.60B | $452.73M | $2.12B | $0.00 | $152.99M | $186.21M | $76.74M | (m) | 5.75× |
| 2021-09-30 | $2.19B | $373.44M | $1.60B | (m) | $149.79M | $288.47M | $44.16M | (m) | 5.85× |
| 2021-06-30 | $2.27B | $425.02M | $1.70B | $30.00M | $127.52M | $268.76M | $76.68M | (m) | 5.33× |
| 2021-03-31 | $2.27B | $364.74M | $1.48B | $256.00M | $118.20M | $240.33M | $76.65M | (m) | 6.23× |
| 2020-12-31 | $2.49B | $416.03M | $1.50B | $435.92M | $101.34M | $231.96M | $111.09M | (m) | 5.97× |
| 2020-09-30 | $2.32B | $378.39M | $1.47B | $341.47M | $121.83M | $220.12M | $74.53M | (m) | 6.14× |
| 2020-06-30 | $2.46B | $354.90M | $1.64B | $421.35M | $104.03M | $179.65M | $91.66M | (m) | 6.93× |
| 2020-03-31 | $2.55B | $306.43M | $1.76B | $406.94M | $106.88M | $173.17M | $26.59M | (m) | 8.31× |
| 2019-12-31 | $1.47B | $264.77M | $835.08M | $289.67M | $90.88M | $171.38M | $68.09M | (m) | 5.55× |
| 2019-09-30 | $1.36B | $215.86M | $724.83M | $324.06M | $68.03M | $166.36M | $81.95M | (m) | 6.31× |
| 2019-06-30 | $1.43B | $162.09M | $808.59M | $294.48M | $56.98M | $156.57M | $44.05M | (m) | 8.81× |
| 2019-03-31 | $1.67B | $137.37M | $732.19M | $612.02M | $50.51M | $140.47M | $26.50M | (m) | 12.17× |
| 2018-12-31 | $1.43B | $173.69M | $370.83M | $803.08M | $49.04M | $125.44M | $33.83M | (m) | 8.21× |
| 2018-09-30 | $1.01B | $114.39M | $209.70M | (m) | $48.60M | $115.82M | $20.41M | (m) | 8.85× |
| 2018-06-30 | $1.14B | $104.69M | $410.38M | (m) | $42.98M | $104.13M | $17.38M | (m) | 10.88× |
| 2018-03-31 | $1.22B | $91.20M | $557.23M | (m) | $39.85M | $99.38M | $17.38M | (m) | 13.37× |
| 2017-12-31 | $1.23B | $88.33M | $599.69M | $479.37M | $29.47M | $83.61M | $8.47M | (m) | 13.91× |
| 2017-09-30 | $735.61M | $70.47M | $617.63M | (m) | $24.75M | $64.69M | $5.32M | (m) | 10.44× |
| 2017-06-30 | $390.58M | $65.96M | $168.35M | (m) | $17.79M | $41.75M | $10.92M | (m) | 5.92× |
| 2017-03-31 | $457.31M | $74.63M | $274.72M | (m) | $12.28M | $30.45M | $27.45M | (m) | 6.13× |
| 2016-12-31 | $373.48M | $75.42M | $122.42M | (m) | $5.23M | $12.81M | $29.69M | (m) | 4.95× |
| 2016-09-30 | $434.74M | $64.93M | $395.14M | (m) | $3.99M | $2.92M | $20.68M | (m) | 6.70× |
| 2016-06-30 | $153.19M | $66.93M | $111.82M | (m) | $3.98M | (m) | $17.13M | (m) | 2.29× |
| 2016-03-31 | $160.73M | $55.16M | $38.00M | (m) | $3.99M | (m) | $18.67M | (m) | 2.91× |
| 2015-12-31 | $224.54M | $62.29M | $80.30M | (m) | $3.98M | (m) | $20.23M | (m) | 3.60× |
| 2015-09-30 | $122.11M | $37.67M | $55.82M | (m) | $2.73M | (m) | $7.43M | (m) | 3.24× |
| 2015-06-30 | $182.39M | $38.96M | $69.54M | (m) | $2.42M | (m) | $14.10M | (m) | 4.68× |
| 2015-03-31 | $193.05M | $33.91M | $74.44M | (m) | $2.42M | (m) | $9.32M | $99.00K | 5.69× |
| 2014-12-31 | $247.80M | $36.87M | $73.55M | (m) | $2.42M | (m) | $12.41M | (m) | 6.72× |
| 2014-09-30 | $269.81M | $22.73M | $52.30M | (m) | $3.36M | (m) | $967.00K | $97.00K | 11.87× |
| 2014-06-30 | $304.67M | $29.40M | $102.75M | (m) | $5.23M | (m) | $1.31M | $96.00K | 10.36× |
| 2014-03-31 | $249.37M | $37.76M | $49.10M | (m) | $7.85M | (m) | $7.72M | $94.00K | 6.60× |
| 2013-12-31 | $270.81M | $35.97M | $256.96M | (m) | $3.53M | (m) | $8.08M | $92.00K | 7.53× |
| 2013-09-30 | $290.42M | $51.10M | $273.64M | (m) | $6.72M | (m) | $8.13M | $91.00K | 5.68× |
| 2013-06-30 | $172.91M | $92.43M | $156.19M | (m) | $3.79M | (m) | $6.73M | $90.00K | 1.87× |
| 2013-03-31 | $176.59M | $103.66M | $167.92M | (m) | $5.65M | (m) | $7.07M | $90.00K | 1.70× |
| 2012-12-31 | $193.91M | $78.89M | $187.66M | (m) | $4.71M | (m) | $7.53M | $89.00K | 2.46× |
| 2012-09-30 | $42.16M | $55.20M | $37.99M | (m) | $2.47M | (m) | $4.33M | $88.00K | 0.76× |
| 2012-06-30 | $33.23M | $17.13M | $24.49M | (m) | $7.18M | (m) | $8.81M | $87.00K | 1.94× |
| 2012-03-31 | $37.63M | $29.92M | $30.57M | (m) | $5.13M | (m) | $8.20M | $86.00K | 1.26× |
| 2011-12-31 | $45.18M | $20.60M | $39.90M | (m) | $3.63M | (m) | $9.40M | $85.00K | 2.19× |
| 2011-09-30 | $51.95M | $26.53M | $46.36M | (m) | $4.27M | (m) | $7.90M | $84.00K | 1.96× |
| 2011-06-30 | $66.02M | $36.94M | $54.19M | (m) | $10.89M | (m) | $10.97M | $83.00K | 1.79× |
| 2010-12-31 | $37.84M | $45.86M | $33.59M | (m) | $3.22M | (m) | $1.31M | $81.00K | 0.83× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |